New Protocol: Ipilimumab + Nivolumab for MSI-H Colorectal Cancer

Phase 3, multicenter, open-label, randomized clinical trial (CheckMate 8HW)

Unresectable or metastatic colorectal cancer with MSI-H/dMMR status, across all treatment lines

Nivolumab + ipilimumab vs. nivolumab

mPFS: NR vs. 39.3 mos (nivolumab + ipilimumab vs. nivolumab) (HR: 0.62 [0.48-0.81], p=0.0003)

Any grade AEs: 81% vs. 71%

Grade ≥3 AEs: 22% vs. 14%

Treatment-related deaths: 2 vs. 1 (nivolumab + ipilimumab vs. nivolumab)

Andre T,Elez E,Lenz HJ Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Reviewed by Ulas D. Bayraktar, MD on Jan 31, 2025